Validation of NG2-creER transgenic mice in demyelination models in studying multiple sclerosis
MetadataShow full item record
MS is an autoimmune neurodegenerative disease that attacks myelin, a protective sheath that covers neurons within our bodies, which may lead to numbness, tremors, issues with vision, dizziness and more. When researching the efficacy of a therapeutic in neurodegenerative diseases such as multiple sclerosis, it is crucial that the in-vivo model selected for testing allows complete and accurate data collection. Several models attempt to replicate conditions of disease, in which myelin levels have been deliberately reduced in order to study its regrowth. These models (Cuprizone and LPC injection) can be further optimized by validating a new strain of mouse, NG2-creER / Rosa-Optopatch, which will essentially express GFP+ myelin. To validate this mouse line, the following goals were pursued: Confirm NG2+ pre-OLs express GFP in the spinal cord tissue and corpus callosum in our NG2-creER mouse, confirm that myelin formed from NG2+ pre-OLs that have matured into OLs also express GFP and characterize the GFP staining pattern along with other known myelin stains (MBP, Fluoromyelin Red), and in the long run, use the NG2-creER model in MS-related targets for drug candidates as a more efficient option than traditional methods such as electron microscopy (EM). Results show that the NG2-creER mouse was successful (in both CPZ and LPC models) in showing NG2+/GFP+ cells and that these GFP+ pre-OLs matured to form GFP+ myelin, as well as showing the capability of staining myelin at a younger age than other myelin stains.
RightsAttribution 4.0 International